<DOC>
	<DOCNO>NCT02652728</DOCNO>
	<brief_summary>Paediatric clinical trial 50 child , 1 month less 12 year age , suffer heart failure due dilate cardiomyopathy , obtain paediatric pharmacokinetic pharmacodynamic data enalapril active metabolite enalaprilat treat 8 week enalapril form Orodispersible Minitablets ( ODMTs ) , describe dose exposure patient population .</brief_summary>
	<brief_title>Orodispersible Minitablets Enalapril Children With Heart Failure Due Dilated Cardiomyopathy</brief_title>
	<detailed_description>This clinical trial one three clinical trial European-Commission ( FP7 ) -funded `` LENA '' ( Labeling Enalapril Neonates Adolescents ) project : 50 child heart failure due dilate cardiomyopathy ( LENA-Work Package ( WP ) 08 Trial ) 50 child heart failure due congenital heart disease ( LENA-WP09 Trial ) get treat optimal dose enalapril ODMTs 8 week thorough , individualise titration get invite join 10 month Safety Follow-up Study ( LENA-WP10 Trial ) . In WP08 Trial child 1 month less 12 year , naive enalapril treatment switch Angiotensin-Converting Enzyme ( ACE ) -Inhibitor pre-treatment , receive Initial Dose investigate reaction 8 hour decision first dose make . Always 7 day later next high dose give hospital , patient supervise 4 always 2 hour decision prescribe dose next dosing period make . In study protocol target dose similar adult target dose ( 20 mg Enalapril 70 year old adult result 0.282 mg/kg/day enalapril ) define . Enalapril ODMTs 0.25 mg 1 mg available allow individual dose titration scheme . Weight-dependently , pharmacokinetic ( PK ) pharmacodynamic ( PD ) data collect full PK/PD day 12 , respectively 6 hour , single PK/PD sample Dose Titration Visit bi-weekly Study Control Visit Last Visit 8 week treatment . Blood pressure renal monitoring perform visit decide dose level next treatment period . Pharmacogenomics metabolomics exploratory study add sub-study good understand underlie disease , progression well impact ACE-inhibition cardiac outcome renal function .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>Patients present heart failure sign leave ventricular ( LV ) systolic dysfunction eligible receive ACEInhibitors addition standard therapy ( e.g. , digitalis diuretic ) enrol trial . Patients previously present LV systolic dysfunction already treated ACEInhibitors , currently still indication use ACEInhibitor switch equivalent start dose enalapril ODMT . Patients fulfil follow inclusion criterion enrol Age 1 month less 12 year . Male female patient . Diagnosis dilate cardiomyopathy present LV enddiastolic dimension &gt; P95 and/or LV shorten fraction ( SF ) &lt; 25 % Subjects may naïve ACEInhibitor . Subjects already ACEInhibitor willing switch enalapril Orodispersible Minitablets . Written inform consent parent ( ) /legal representative assent patient accord national legislation far achievable child . Patients fulfil follow exclusion criterion enrol trial : Severe heart failure and/or end stage heart failure preclude introduction continuation ACEInhibitor . Too low blood pressure , e.g . ˂P5 Restrictive hypertrophic cardiomyopathy . Obstructive valvular disease ( peak echocardiographic gradient 30 mm Hg ) . Uncorrected severe peripheral stenosis large artery include severe coarctation aorta . Severe renal impairment serum creatinine &gt; 2x Upper Limit Normal ( ULN ) ( accord hospital 's test methodology ) . History angioedema . Hypersensitivity ACEInhibitor . Concomitant medication : Dual ACEInhibitor therapy Renin inhibitor Angiotensin II antagonists NonSteroidal AntiInflammatory Drugs ( include ibuprofen ) except aspirin paracetamol Already enrol interventional trial investigational drug , unless interference current study show .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>